Dogwood Therapeutics, Inc.

DWTX Nasdaq SEC CIK 1818844
Follow Dogwood Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $100K
Net income −$4.9M +69% vs same quarter last year
EPS, diluted −$0.14 +98.3% vs same quarter last year
Operating cash flow −$4.6M −41.7% vs same quarter last year
Net income by quarter
−$7.7M
−$10.9M
−$3.8M
−$15.7M
−$3.8M
−$5M
−$11.5M
−$4.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$40M−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$34.3M
FY24−$12.3M
FY23−$5.3M
FY22−$12.2M
FY21−$16M
FY20−$10.3M
FY19-